Pharming Group Nv Stock Performance
| PHAR Stock | USD 9.92 0.33 3.22% |
On a scale of 0 to 100, Pharming Group holds a performance score of 7. The company holds a Beta of 0.92, which implies possible diversification benefits within a given portfolio. Pharming Group returns are very sensitive to returns on the market. As the market goes up or down, Pharming Group is expected to follow. Please check Pharming Group's standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Pharming Group's historical price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pharming Group NV are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile basic indicators, Pharming Group reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.55) | Five Day Return 2.64 | Year To Date Return (1.97) | Ten Year Return (38.60) | All Time Return (38.60) |
1 | Pharming Group Receives NICE Approval for Joenja in England and Wales PHAR Stock News | 04/23/2025 |
2 | Pharming Group reports first quarter 2025 financial results and provides business update - Stock Titan | 05/07/2025 |
3 | Pharming Group Shares Gap Down Heres Why | 05/30/2025 |
4 | Pharming Group Sees Strong Trading Volume Whats Next | 06/13/2025 |
5 | Pharming Group to Host Webcast on New APDS Study Findings - TipRanks | 06/24/2025 |
6 | KalVista Pharmaceuticals rises after FDA nod for Ekterly - Seeking Alpha | 07/07/2025 |
| Begin Period Cash Flow | 61.7 M | |
| Total Cashflows From Investing Activities | 31.6 M |
Pharming Group Relative Risk vs. Return Landscape
If you would invest 839.00 in Pharming Group NV on April 22, 2025 and sell it today you would earn a total of 186.00 from holding Pharming Group NV or generate 22.17% return on investment over 90 days. Pharming Group NV is currently generating 0.4052% in daily expected returns and assumes 4.0911% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Pharming, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pharming Group Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharming Group's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pharming Group NV, and traders can use it to determine the average amount a Pharming Group's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.099
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PHAR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.09 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Pharming Group is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharming Group by adding it to a well-diversified portfolio.
Pharming Group Fundamentals Growth
Pharming Stock prices reflect investors' perceptions of the future prospects and financial health of Pharming Group, and Pharming Group fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharming Stock performance.
| Return On Equity | -0.0678 | ||||
| Return On Asset | 0.0199 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 714.09 M | ||||
| Shares Outstanding | 68.39 M | ||||
| Price To Earning | 41.53 X | ||||
| Price To Book | 3.28 X | ||||
| Price To Sales | 2.19 X | ||||
| Revenue | 297.2 M | ||||
| Gross Profit | 285.37 M | ||||
| EBITDA | 7.19 M | ||||
| Net Income | (10.64 M) | ||||
| Cash And Equivalents | 189.96 M | ||||
| Cash Per Share | 2.91 X | ||||
| Total Debt | 108.42 M | ||||
| Debt To Equity | 0.75 % | ||||
| Current Ratio | 5.22 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (1.79 M) | ||||
| Earnings Per Share | (0.21) X | ||||
| Market Capitalization | 701.27 M | ||||
| Total Asset | 386.88 M | ||||
| Retained Earnings | (265.36 M) | ||||
| Working Capital | 204.64 M | ||||
About Pharming Group Performance
Assessing Pharming Group's fundamental ratios provides investors with valuable insights into Pharming Group's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Pharming Group is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 554.87 | 527.13 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.03) | (0.03) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.05) | (0.05) |
Things to note about Pharming Group NV performance evaluation
Checking the ongoing alerts about Pharming Group for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharming Group NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharming Group NV had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 297.2 M. Net Loss for the year was (10.64 M) with profit before overhead, payroll, taxes, and interest of 285.37 M. | |
| Pharming Group NV currently holds about 189.96 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91. | |
| Pharming Group NV has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: KalVista Pharmaceuticals rises after FDA nod for Ekterly - Seeking Alpha |
- Analyzing Pharming Group's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharming Group's stock is overvalued or undervalued compared to its peers.
- Examining Pharming Group's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharming Group's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharming Group's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharming Group's stock. These opinions can provide insight into Pharming Group's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.